Nicholas Lydon

Nicholas Lydon (board member) discloses dealings in 2 companies, chiefly Blueprint Medicines Corp and Anaptysbio, Inc. Between 31 January 2017 and 12 June 2024, the trades on record add up to 41 filings.

In open-market terms, that means 1 purchase worth €233k on one side and 29 sales worth €14.5M on the other. Taken together, the sales exceed the purchases by €14.3M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 5 share grants and 3 option exercises.

On 14 June 2024 came the latest disclosure, a share grant in Blueprint Medicines Corp. The last insider purchase was made public on 31 January 2017, 3,569 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.